Back to Search
Start Over
The WNT Pathway Is Relevant for the BCR-ABL1-Independent Resistance in Chronic Myeloid Leukemia
- Source :
- Frontiers in Oncology, Vol 9 (2019), Frontiers in oncology 9 (2019). doi:10.3389/fonc.2019.00532, info:cnr-pdr/source/autori:Grassi, Susanna; Palumbo, Sara; Mariottit, Veronica; Liberati, Diego; Guerrini, Francesca; Ciabatti, Elena; Salehzadeh, Serena; Barate, Claudia; Balducci, Serena; Ricci, Federica; Buda, Gabriele; Iovino, Lorenzo; Mazziotta, Francesco; Ghio, Francesco; Ercolano, Giacomo; Di Paolo, Antonello; Cecchettini, Antonella; Baldini, Chiara; Mattii, Letizia; Pellegrini, Silvia; Petrini, Mario; Galimberti, Sara/titolo:The WNT Pathway Is Relevant for the BCR-ABL1-Independent Resistance in Chronic Myeloid Leukemia/doi:10.3389%2Ffonc.2019.00532/rivista:Frontiers in oncology/anno:2019/pagina_da:/pagina_a:/intervallo_pagine:/volume:9, Università di Pisa-IRIS, Frontiers in oncology (2019)., info:cnr-pdr/source/autori:Susanna Grassi1*, Sara Palumbo2, Veronica Mariotti3, Diego Liberati4, Francesca Guerrini5, Elena Ciabatti5, Serena Salehzadeh5, Claudia Baratè5, Serena Balducci5, Federica Ricci5, Gabriele Buda5, Lorenzo Iovino5, Francesco Mazziotta5, Fracesco Ghio5, Giacomo Ercolano5, Antonello Di Paolo6, Antonela Cecchettini3, Chiara Baldini6, Letizia Mattii3, Silvia Pellegrini3, Mario Petrini5, Sara Galimberti5*/titolo:The Wnt Pathway is Relevant for the BCR-ABL-1 Independent Resistance in Chronic Myeloid Leukemia/doi:/rivista:Frontiers in oncology/anno:2019/pagina_da:/pagina_a:/intervallo_pagine:/volume, Frontiers in Oncology
- Publication Year :
- 2019
- Publisher :
- Frontiers Media S.A., 2019.
-
Abstract
- Notwithstanding the introduction of Tyrosine Kinase Inhibitors (TKIs) revolutionized the outcome of Chronic Myeloid Leukemia (CML), one third of patients still suspends treatment for failure response. Recent research demonstrated that several BCR/ABL1-independent mechanisms can sustain resistance, but the relationship between these mechanisms and the outcome has not yet been fully understood. This study was designed to evaluate in a “real-life” setting if a change of expression of several genes involved in the WNT/BETA-CATENIN, JAK-STAT, and POLYCOMB pathways might condition the outcome of CML patients receiving TKIs. Thus, the expression of 255 genes, related to the aforementioned pathways, was measured by quantitative PCR after 6 months of therapy and compared with levels observed at diagnosis in 11 CML patients, in order to find possible correlations with quality of response to treatment and event-free-survival (EFS). These results were then re-analyzed by the principal component method (PCA) for tempting to better cluster resistant cases. After 12 months of therapy, 6 patients achieved an optimal response and 5 were “resistant;” after application of both statistical methods, it was evident that in all pathways a significant overall up-regulation occurred, and that WNT was the pathway mostly responsible for the TKIs resistance. Indeed, 100% of patients with a “low” up-regulation of this pathway achieved an optimal response vs. 33% of those who showed a “high” gene over-expression (p = 0.016). Analogously, the 24-months EFS resulted significantly influenced by the degree of up-regulation of the WNT signaling: all patients with a “low” up-regulation were event-free vs. 33% of those who presented a “high” gene expression (p = 0.05). In particular, the PCA analysis confirmed the role of WNT pathway and showed that the most significantly up-regulated genes with negative prognostic value were DKK, WNT6, WISP1, and FZD8. In conclusion, our results sustain the need of a wide and multitasking approach in order to understand the resistance mechanisms in CML.
- Subjects :
- 0301 basic medicine
Oncology
Cancer Research
medicine.medical_specialty
Wnt/β‐catenin
lcsh:RC254-282
WNT6
03 medical and health sciences
BCR/ABL1-indpedent resistane
0302 clinical medicine
Internal medicine
Gene expression
BCR/ABL1‐indpedent resistane
Medicine
CML
Original Research
PcGs
Wnt/β‐catenin, JAK/STAT, PcGs, BCR/ABL1‐indpedent resistane, CML, PCA
PCA
business.industry
breakpoint cluster region
Wnt signaling pathway
JAK-STAT signaling pathway
Myeloid leukemia
WNT/β-catenin
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
JAK/STAT
030104 developmental biology
Real-time polymerase chain reaction
BCR/ABL1-independent resistance
030220 oncology & carcinogenesis
business
WNT/beta-catenin
Tyrosine kinase
Wnt/?-catenin
Subjects
Details
- Language :
- English
- Volume :
- 9
- Database :
- OpenAIRE
- Journal :
- Frontiers in Oncology
- Accession number :
- edsair.doi.dedup.....5e30a38fb09e960d53d2c9dd6b3f85f0
- Full Text :
- https://doi.org/10.3389/fonc.2019.00532/full